Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Solicitation opportunity from Department Of Defense was posted on June 25, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

DoW Neurofibromatosis Investigator-Initiated Research Award

Closed
HT942526NFRPIIRAGrant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541715
New
Federal
U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911PT26SC001
The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.
W6QK Acc Wva

POSTED

about 7 hours ago

DEADLINE

in 12 months

AI Contract Overview

Show more

The FY26 Neurofibromatosis Research Program Investigator-Initiated Research Award (IIRA), solicitation number HT942526NFRPIIRA, is a funding opportunity issued by the Defense Health Agency to support high-impact research addressing critical needs in neurofibromatosis disorders and patient care. The program supports any phase of research except for clinical trials and requires applications to include relevant preliminary or published data. Awards are structured into two funding levels: Level 1 for standard applications with a cost cap of $840,000, and Level 2 for applications utilizing the Open Science Initiative or the Qualified Collaborator option, which carries a cost cap of $920,000. The maximum period of performance for these awards is three years. The application process is a two-step requirement, starting with a Letter of Intent due by September 8, 2026, followed by a full application due by September 22, 2026. Submissions must be made via eBRAP for intramural organizations or through the Grants.gov Workspace for extramural organizations. Evaluation follows a two-tier process consisting of a peer review for technical merit and a programmatic review for relevance to FY26 NFRP priorities. Key requirements include active registration in SAM.gov, eBRAP, and Grants.gov, as well as the disclosure of all foreign affiliations for key personnel. Total program funding is approximately $6.04 million, intended to support roughly five Level 1 and two Level 2 awards.

General Info

DHA funding for neurofibromatosis research; max $920,000 per award over three years.

Documents

1

FY26 Neurofibromatosis Research Program Investigator-Initiated Research Award HT942526NFRPIIRA

PDF, High priority: read this firstrfp
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca
Contacts1 person available
OfficeUSA

Full Description

Show more

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Investigator-Initiated Research Award (IIRA) supports high-impact research that addresses a critical need and has the potential to make important contributions to the field of neurofibromatosis disorders or advance patient care. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to NF and the proposed research project.


Distinctive Features: This award mechanism offers two funding levels based on participation in two optional features:

• Open Science Initiative: Catalyzes research for neurofibromatosis through early access to data and data sharing within the neurofibromatosis community.

• Optional Qualified Collaborator: Encourages collaborative research between basic scientists and clinical researchers, and between academic and biotechnology scientists.

The funding levels are defined as follows:

• Level 1: Applications without an optional feature.

• Level 2: Applications including one of the optional features.

More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

Same awarding agency

NAICS: 541715
Grant
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Solicitation # HT942526BCRPBTA122
The Defense Health Agency Contracting Activity is soliciting applications for the Fiscal Year 2026 Breast Cancer Research Program Breakthrough Award Levels 1 and 2 under solicitation HT942526BCRPBTA122. This program aims to fund high-impact research capable of producing breakthroughs in breast cancer treatment and understanding. Funding Level 1 supports early-stage, high-risk, high-reward research focused on proof of concept without requiring preliminary data, while Funding Level 2 supports research validated by substantial preliminary or published data to facilitate clinical translation. A specialized Population Science Studies option is available under Level 2. The program expects to allot approximately 10.6 million dollars to fund roughly six applications. Eligible applicants may apply as a single Principal Investigator or through a Partnering PI Option. Funding limits vary by level and PI structure, ranging from 750,000 dollars for a single PI at Level 1 up to 3.35 million dollars for partnering PIs conducting Population Science Studies at Level 2. The maximum period of performance is three years, extending to four years for Population Science Studies. Applications are evaluated based on impact, research strategy, and feasibility, with personnel and partnership qualifications also considered. The application process is a two-step submission requiring a pre-application by November 4, 2026, and a full application by November 18, 2026. Required documentation includes a project narrative, statement of work, and various abstracts and statements submitted as specific PDF attachments. Applicant organizations must maintain active registration in SAM.gov and provide a Unique Entity Identifier. Additionally, all key personnel must disclose foreign affiliations, and clinical research proposals must include a Public Health Service Inclusion Enrollment Report.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 2 months ago

DEADLINE

in 29 days
View Details
NAICS: 541715
Grant
DoW Breast Cancer, Clinical Research Extension Award
Solicitation # HT942526BCRPCREA2
The FY26 Breast Cancer Research Program Clinical Research Extension Award, solicitation HT942526BCRPCREA2, is a grant opportunity issued by the Defense Health Agency Contracting Activity to support research that extends data collection, follow-up, and analysis of breast cancer clinical studies. The program aims to recover knowledge lost due to early trial termination, limited patient follow-up, or suboptimal data collection, including projects involving deeper molecular analysis of clinical samples. All applications must address at least one FY26 BCRP overarching challenge. The research team is required to include at least two breast cancer consumer advocates. Funding allows for a single Principal Investigator or a partnering arrangement between an Initiating PI and a Partnering PI. The application process is a two-step submission requiring a pre-application Letter of Intent by November 4, 2026, and a full application by November 18, 2026. Pre-applications are submitted via eBRAP, while full applications are submitted through eBRAP for intramural DOW organizations and Grants.gov for extramural organizations. Awards have a maximum period of performance of four years. Evaluation follows a two-tier system consisting of a peer review for technical merit and a programmatic review for relevance. Scored criteria include impact, research strategy and feasibility, partnership (for PPIO applications), and the research sharing plan. Applicants must be registered in SAM.gov with an active status and a Unique Entity Identifier.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 2 months ago

DEADLINE

in 29 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS